Kieran McCafferty

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

Rachael A Evans, Hamish McAuley, Ewen M. Harrison et al. · The Lancet Respiratory Medicine · 2021 · 659 citations · Full text

Medicine, Health Sciences, Psychiatry +17

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal et al. · Kidney International Reports · 2021 · 165 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17